A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
European Journal of Cancer2014Vol. 50(12), pp. 2072–2081
Citations Over TimeTop 1% of 2014 papers
Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park, Chung‐Pin Li, M. E. Scheulen, Saifuddin M. Kasubhai, Do‐Youn Oh, Yuan Liu, Suman Redhu, Klaudia Steplewski, Ngocdiep T. Le
Related Papers
- → Trametinib in the treatment of melanoma(2015)39 cited
- → Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor(2020)7 cited
- → Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma(2023)6 cited
- → The MEK inhibitor trametinib for the treatment of advanced melanoma(2014)
- → Abstract B90: HSP90 inhibitor NVP-AUY922 sensitizes intrinsic MEK inhibitor Trametinib-resistant NSCLC cells harboring KRAS mutation(2015)